24.55SEK-1.80%Mkt Cap: 1.16B SEKP/E: —Last update: 2026-06-01
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.16B SEK
Enterprise Value1.07B SEK
Revenue (TTM)2.47M SEK
Gross Profit2.47M SEK
Net Income (TTM)-171.44M SEK
Revenue/Share0.0620 SEK
Last Price24.55 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees24
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.72
PEG—
EV/EBITDA-7.25
EV/Revenue434.18
P/S480.70
P/B1.73
EPS (TTM)-4.10
EPS (Forward)-1.59
52W Range
22.465% of range64.10
52W High64.10 SEK
52W Low22.46 SEK
Profitability
Gross Margin100.00%
Oper. Margin-6095.46%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.35%
ROA-22.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-193.16M SEK
CapEx (TTM)29.19M SEK
FCF Margin-4788.44%
FCF Yield-10.14%
Net Debt27.13M SEK
Net Debt/EBITDA-0.18
Balance Sheet
Debt/Equity0.25
Current Ratio1.02
Quick Ratio0.84
Book Value/Sh14.48 SEK
Cash/Share2.892 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)60.00 SEK
Target Range60.00 SEK – 60.00 SEK
# Analysts1
Ownership
Shares Out.47.42M
Float29.86M
Insiders28.34%
Institutions42.03%
Technical
SMA 5026.25 (-6.5%)
SMA 20031.08 (-21.0%)
Beta-0.06
S&P 52W Chg27.70%
Avg Vol (30d)105.76K
Avg Vol (10d)123.98K
Technical Indicators
RSI (14)49.1
MACD-0.5066
MACD Signal-0.5691
MACD Hist.+0.0625
BB Upper25.99 SEK
BB Middle24.55 SEK
BB Lower23.11 SEK
BB Width11.75%
ATR (14)1.231 SEK
Vol Ratio (20d)2.01x